myelodysplastic syndromes (MDS) | Page 5 | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

Aplastic Anemia, MDS, and PNH Virtual Support Group -Saturdays- 2023 August

Event Date: 
Sat, 08/26/2023 - 10:30am (EDT)

AAMDSIF is pleased to announce that we will host a support group for patients diagnosed with

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T
Primary Author: 
Platzbecker U
Journal Title: 
Original Publication Date: 
Jun 2023

Background: Erythropoiesis-stimulating agents (ESAs) are the standard-of-care treatment for anaemia in most patients with lower-risk

Bone Marrow Disease(s): 
Share with